| Date Filed | Type | Description |
| 08/11/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/12/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/13/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 12/16/2022 |
SC 13D/A
| Nan Fung Group Holdings Ltd reports a 0.7% stake in Eargo, Inc. |
| 08/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/13/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/15/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 09/22/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/29/2020 |
SC 13D
| Nan Fung Group Holdings Ltd reports a 7.7% stake in Eargo, Inc. |
| 01/09/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/02/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 12/31/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/15/2019 |
SC 13D
| Nan Fung Group Holdings Ltd reports a 7.2% stake in Stealth BioTherapeutics Corp. |